MARKET

PLSE

PLSE

Pulse
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.97
+1.66
+10.18%
After Hours: 17.97 0 0.00% 16:42 05/11 EDT
OPEN
16.17
PREV CLOSE
16.31
HIGH
18.23
LOW
14.59
VOLUME
121.14K
TURNOVER
--
52 WEEK HIGH
45.82
52 WEEK LOW
7.73
MARKET CAP
474.37M
P/E (TTM)
-8.3605
1D
5D
1M
3M
1Y
5Y
What You Need To Know About Pulse Biosciences, Inc.'s (NASDAQ:PLSE) Investor Composition
A look at the shareholders of Pulse Biosciences, Inc. ( NASDAQ:PLSE ) can tell us which group is most powerful...
Simply Wall St. · 17h ago
H.C. Wainwright Reiterates a Buy Rating on Pulse Biosciences (PLSE)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Pulse Biosciences (PLSE), with a price target of
SmarterAnalyst · 18h ago
8-K: Pulse Biosciences, Inc.
(EDGAR Online via COMTEX) -- plse-20210510x8k false000162510100016251012021-05-102021-05-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C....
Edgar Online - (EDK = 8-Ks/S1/S-4) · 1d ago
DJ Pulse Biosciences, Inc. CEO Darrin Uecker on Q1 2021 Results -- Earnings Call Transcript >PLSE
Dow Jones · 1d ago
BRIEF-Pulse Biosciences Posts Q1 Loss Per Share Of 71 Cents
reuters.com · 1d ago
Pulse Biosciences Reports First Quarter 2021 Financial Results
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing its Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the first quarter of 2021.
Business Wire · 1d ago
10-Q: PULSE BIOSCIENCES, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 1d ago
Pulse Biosciences Q1 EPS $(0.71) Misses $(0.49) Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.49) by 44.9 percent. This is a 24.56 percent decrease over losses of $(0.57) per share
Benzinga · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PLSE. Analyze the recent business situations of Pulse through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PLSE stock price target is 43.00 with a high estimate of 46.00 and a low estimate of 40.00.
EPS
Institutional Holdings
Institutions: 71
Institutional Holdings: 3.12M
% Owned: 11.83%
Shares Outstanding: 26.40M
TypeInstitutionsShares
Increased
18
92.61K
New
9
138.84K
Decreased
18
55.70K
Sold Out
1
18.78K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.23%
Healthcare Equipment & Supplies
-0.50%
Key Executives
Chairman/Independent Director
Robert Duggan
President/Chief Executive Officer/Director
Darrin Uecker
Chief Financial Officer/Executive Vice President - Finance/Treasurer/Secretary
Sandra Gardiner
Executive Vice President/General Manager
Edward Ebbers
Independent Director
Kenneth Clark
Independent Director
Mitchell Levinson
Independent Director
Manmeet Soni
Independent Director
Mahkam Zanganeh
No Data
About PLSE
Pulse Biosciences, Inc. is a clinical-stage medical device company using a platform technology called Nano-Pulse stimulating (NPS). NPS is a non-thermal, precise, focal drug-free electroceutical treatment technology that initiates cell death within treated tissue. NPS provides treatment in a range of immuno-oncology, dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret's esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing PulseTx system (PulseTx), a system for the delivery of NPS treatments. The PulseTx system delivers NPS pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.

Webull offers kinds of Pulse Biosciences Inc stock information, including NASDAQ:PLSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLSE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLSE stock methods without spending real money on the virtual paper trading platform.